C ontinuous-flow left ventricular assist devices (CF-LVADs) have become the standard of care for medically refractory, end-stage heart failure as either bridge to transplant or destination therapy. [1] [2] [3] In spite of their success in improving mortality and quality of life, thrombotic and bleeding events remain significant complications. 1 In a secondary analysis of the HeartMate II Bridge-to-Transplant (BTT) trial, the incidence of thrombotic events (confirmed pump thrombosis and ischemic stroke) and hemorrhagic events within 6 months of discharge were found to be 2.7% and 12.9%, respectively. 4 Whereas the trial by the HeartMate II investigators specified an international normalized ratio (INR) goal of 2.0 to 3.0, 2 the relatively greater burden of hemorrhagic events in this trial and the HeartMate II BTT trial 4 fostered the conclusion that a target INR of 1.5 to 2.5 (in addition to aspirin therapy) might be safer. Single-center studies also found low rates of thrombotic events and suggested that INRs <2.0 were acceptable as was withholding warfarin for those at high risk of bleeding. 5 Practice patterns, therefore, have tended toward lower INR goals.
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Over time, the question of anticoagulation in left ventricular assist device (LVAD) support has become complicated. In the HeartMate II destination therapy pivotal study, the incidence of thrombotic events (defined as confirmed pump thrombosis or ischemic stroke) was higher than the BTT trial study-16% at 1.7 years of follow-up. 2 The pivotal study used warfarin with a goal INR between 2.0 and 3.0, in addition to aspirin. Subsequently, analysis of the HeartWare ADVANCE noted INR <2.0 as a risk factor for pump thrombosis. 6 Finally, more recently, others have reported an increase in pump thrombosis among CF-LVADs, especially within the first 6 months of implant. 7, 8 The reason for increased thrombosis is not clear but is likely multifactorial, with gastrointestinal bleeding (GIB), infection, varying anticoagulation bridging strategies, and suboptimal INRs potentially contributing. In addition, patient selection has changed since Food and Drug Administration Anticoagulation, Thrombosis, and Bleeding in LVADs approval for destination therapy in January 2010, allowing more implants in patients potentially at higher risk of thrombosis. The objective of this study was to examine the association between INR and both thrombotic and hemorrhagic events among outpatients supported with CF-LVADs.
Methods

Study Population
We retrospectively identified patients who underwent implantation of a HeartMate II (Thoratec Corp, Pleasanton, CA) or HVAD (HeartWare Corp, Framingham, MA) between January 2005 and August 2013 at our center. Inclusion criteria for the present study were CF-LVAD placement, age ≥18 years, survived to discharge, and followed up at our institution. Exclusion criteria included patients who underwent repeat LVAD implantation (ie, pump exchange) or patients who had a hemorrhagic or thrombotic event before discharge from their implant hospitalization.
Patients were censored at the time of transplantation, LVAD explant or exchange, death, or last known follow-up. To avoid confounding by indication, patients were censored at their first hemorrhagic event (intracranial hemorrhage [ICH] or GIB) or thrombotic event (suspected pump thrombosis or ischemic stroke), that is, a patient could only contribute a maximum of 1 thrombotic event or 1 hemorrhagic event. Only events occurring outside of the hospital were included; if a patient had a thrombotic or hemorrhagic event while an inpatient they were censored.
Data Collection
Clinical data, including baseline characteristics, medications, blood products, and outcomes, were abstracted from the electronic medical record. The data were managed in the Research Electronic Data Capture database. 9 The Institutional Review Board at Washington University in St. Louis approved the study.
Institutional protocol dictates that outpatient INRs are checked weekly when not in therapeutic range and every other week when within the therapeutic range. The target therapeutic range for our patients supported with HeartMate II evolved was 2.0 to 2.5 from 2005 to 2008, 1.5 to 2.0 from 2008 to 2010, and 2.0 to 3.0 from 2010 to current. The target INR range for patients supported with HeartWare HVAD was 2.0 to 3.0 throughout.
We used the INR at the time of the adverse event. In patients treated with vitamin K, fresh frozen plasma, or blood transfusion before measuring the INR, we used the INR before treatment. In patients admitted with a pump thrombosis, we used the last available outpatient INR (because pump thrombosis often starts with a subclinical phase and can elevate the INR).
Definitions and Outcomes
Suspected pump thrombosis was defined as observation of obstructive thrombus in the pump or conduit post pump exchange or severe hemolysis. Severe hemolysis was defined as lactate dehydrogenase level >1000 mg/dL (4× the upper limit of normal for our laboratory) or plasma-free hemoglobin level >40 mg/dL with symptoms of decompensated heart failure in the absence of a kinked inflow or outflow cannula. An lactate dehydrogenase value >3.5× the upper limit of normal has excellent specificity and sensitivity for the diagnosis of pump thrombosis. 10 GIB was defined as clinically evident or occult GIB prompting hospital admission and endoscopic evaluation. Severe anemia requiring blood transfusion in the absence of hemolysis and a bleeding source was classified as occult bleeding.
Stroke was identified as an acute neurological deficit persisting for >24 hours. A stroke was classified as hemorrhagic or ischemic based on head computed tomography. If the head computed tomography was read as ischemic stroke with hemorrhagic conversion or both ischemic and hemorrhagic strokes, then the stroke was classified as ischemic.
Weights of Thrombotic and Bleeding Events
To balance the benefits and risks of more intensive anticoagulation, events were weighted based on their expected 30-day mortality rates. Mortality rates were calculated from the onset of adverse event by averaging internal data based on 455 patients with CF-LVAD (Appendix I in the Data Supplement) with published mortality data of ischemic stroke, 11, 12 ICH, 12, 13 GIB, [14] [15] [16] and pump thrombosis. 7, 17 The baseline mortality rate in our LVAD population (n=455) was 0.036 deaths per month. To this baseline mortality, we added the incremental mortality rate (per month) from an adverse event (Appendix I in the Data Supplement): pump thrombosis, 0.16; GIB, 0.01; ischemic stroke, 0.11; and ICH, 0.49. Of note, the mortality rate after LVAD-related GI bleeding varied from 0 to 0.02 deaths per patient-month.
Statistical Analysis
When calculating event rates, the numerator was the number of adverse events. The denominator was days in each INR range as calculated according to the method described by Rosendaal et al 18 for linear interpolation. The rate for each INR category was calculated using Poisson regression via generalized estimating equations to account for correlated data (Appendix I in the Data Supplement).
The optimal INR was determined by combining exponential models created for thrombosis and for bleeding rates. Rates for each INR category were log-transformed, and the mean INR value within each range was used as the independent variable to develop the 2 exponential models. To prevent taking the logarithm of 0, the constant 0.1 was added to each thrombosis rate. (An advantage of this approach is that it avoids relying on the Yates correction for continuity, which is conservative for 2-sided tests with rare events). 19 When developing the exponential models, INR ranges were weighted by the frequency of observations.
The sum of the exponential bleeding and thrombosis models was obtained by weighting each based on mortality-associated event rates obtained independently (as detailed above). This weighted U-shaped curve was then used to determine the optimal INR value that minimized mortality.
The association between INR and clinical events was further quantified in a multivariable analysis that used Cox regression. Time to event was left truncated to account for time 0 being implant date but hazard time not beginning until discharge. Individuals were part of the at-risk group once their first INR was measured. INR was allowed to vary over time to account for repeated measurements taken during follow-up. Separate Cox models were created for both event types (bleeding and thrombosis). Cox models adjusted for age, sex, LVAD type (HeartMate II or HeartWare), history of atrial fibrillation, and history of coronary artery disease as these covariates influence bleeding or thrombotic events. 8, 15, 20 In addition, the interaction of INR and time was investigated to determine if the association between INR and clinical event changed over time. Time was categorized into hospital discharge to 3 months, months, 3 to 6 months, and >6 months based on when INR was obtained from time of implant.
Significance was identified as a 2-sided α of <0.05. Analyses were conducted using SAS version 9.4 (SAS Institute Inc, Cary, NC).
Results
Patient Population
A total of 305 patients received a CF-LVAD from January 2005 until August 2013 and were discharged alive. Fiftysix patients were excluded from analysis: 20 were LVAD exchanges, 11 had thrombotic events during their index stay, 4 were followed up at other institutions, and 21 had incomplete data because of censoring before ≥2 consecutive outpatient INRs were obtained. The analysis cohort consisted of 249 patients. Anticoagulation, Thrombosis, and Bleeding in LVADs
The 249 patients analyzed had a median outpatient follow-up of 17.6±13.6 months with 10 927 INR measurements available, an average of 1 INR every 11.8 days. Most patients were men (81%), classified as Interagency Registry for Mechanically Assisted Circulatory Support profile 2, and bridge-to-transplant approach was used for 69% of the patients (Table 1) . Nearly all patients were discharged on warfarin and aspirin (96%), with 45% of patients being on 325 mg of aspirin and 51% on 81 mg of aspirin. The mean INR at discharge after LVAD implant was 2.18±0.62, and during outpatient follow-up, the mean INR was 2.16±0.77 (Figure 1 ).
Thrombotic Events
A total of 46 thrombotic events occurred: 32 suspected pump thrombosis and 14 ischemic strokes. The highest event rate (0.40 events per patient-year) occurred in the INR range of <1.5, but INR values of 1.5 to 1.99 also had high rates (0.16 thrombotic events per patient-year). Among the INRs >2.5 categories, there was no episode of ischemic stroke and only 1 episode of suspected pump thrombosis (Figure 2A ). Twentythree of the 32 patients who developed the suspected pump thrombosis expired, had pump exchange, or were transplanted within 90 days of hemolysis. Only 3 of the 32 survived for >1 year with their index LVAD with all 3 having resolution of hemolysis with stronger anticoagulants.
In univariate analysis, INR was inversely associated (P=0.002) with thrombotic events (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.22-0.70 per 1-U increase in INR; Table 2 ). In Cox proportional hazard models adjusting for age, sex, atrial fibrillation, coronary disease, and LVAD type, INR remained inversely associated with thrombotic events (HR, 0.40; 95% CI, 0.22-0.72; P=0.002; Table 3 ). The inverse association between INR and thrombotic events was statistically significant for the 3-to 6-month and >6month postimplant timeframe but was not significant before 3 months (HR, 0.75; 95% CI, 0.34-1.65; P=0.47; Table 2 ). The lack of significance between INR and thrombotic events before 3 months was in spite of this period being the time of the highest incidence rate of pump thrombosis (0.37 events per patient-year). Comparing the HR of thrombotic event by INR before 3 months to after 3 months bordered on statistical significance (0.75 versus 0.25; P=0.05).
Hemorrhagic Events
A total of 62 hemorrhagic end points occurred: 53 GI bleeds and 9 ICHs. The highest bleeding event rate (1.4 events per patient year) occurred in the INR range >3.5 and the lowest event rates (≤0.1 events per patient-year) were in with the lowest INR categories ( Figure 2B ). There were 7 episodes of ICH in those with INR >2.5 and only 2 episodes of ICH with INR <2.5.
In univariate analysis, INR was associated with hemorrhage (HR, 1.63; 95% CI, 1.41-1.88; P<0.001; Table 4 ). In a Cox proportional hazard models that adjusted for age, sex, atrial fibrillation, coronary disease, and LVAD type, INR remained associated with hemorrhage (HR, 1.66; 95% CI, 1.43-1.93; P<0.001; Table 5 ). When evaluated with a time interaction to determine whether the relationship of INR and hemorrhagic events changed over time, increased INR remained significant across all time periods (Table 4 ). INR was also found to have a greater association with hemorrhagic events before 3 months versus >3 to 6 months (0-3 months: HR, 2.33 versus >3-6 months: HR, 1.44; P=0.021) and trended toward significance when compared with >6 months (HR, 1.60; P=0.06). 
Discussion
Anticoagulation management of outpatients with CF-LVADs remains a delicate balance between avoiding hemorrhagic and thrombotic complications. Previous studies suggested that low rates of thrombotic events may allow for lower INRs for those at high risk of bleeding, 4,5 but reports of higher rates of thrombosis have cast doubt on this assertion. 7, 8 Here, we characterized the relationship between outpatient management of anticoagulation and both thrombotic and hemorrhagic events occurring outside of the hospital.
By analyzing ≈11 000 outpatient INRs among 249 outpatients, we demonstrated that thrombotic outcomes (suspected pump thrombosis and ischemic stroke) were the highest among the lowest INRs (<1.5), but INR values of 1.5 to 1.99 also had high rates (0.16 thrombotic events per patient-year). Although the finding that lower INR was associated with thrombosis was hypothesized, the observed time-sensitive relationship between INR and thrombosis was unexpected. This lack of a statistically significant association between INR and thrombotic events in the 0-to 3-month timeframe suggests that early pump thrombosis may be affected by INR-independent events during the index hospitalization, such as operative or device characteristics and intensity of postoperative bridging anticoagulation. Conversely, after the early postsurgical period, anticoagulation intensity predicts pump thrombosis.
An optimal INR based on weighted mortality of bleeding and thrombotic events was 2.6. In the future, it might be interesting to develop patient-specific anticoagulation strategies based on risk models that stratify a patient's propensity to have hemorrhagic and thrombotic complications.
Our conclusions differ from an analysis of from the HeartMate II pivotal trial. That study did not find a statistical association between lower INR and thrombotic events, but there were no ischemic strokes when the INR exceeded 2.0. 4 The different conclusions between studies may have been driven by the greater rate of suspected pump thrombosis that we observed (12.9% of patients for a mean follow-up of 17.6 months). Our rate was higher because we included persistent hemolysis in our definition of suspected pump thrombosis. In contrast, the HeartMate II pivotal trial captured only a thrombus in the device or its conduits. Our event rate is commensurate to what Starling et al 7, 21 reported (eg, 12.3% at 1 year of follow-up). Our study had high precision because we included When interpreting the results of our study, several limitations must be considered. The study is retrospective and nonrandomized. To reduce confounding by indication, we censored patients at the time of their first event. However, patients at higher risk of thrombotic events may have been assigned higher INR goals from the outset. Censoring patients after their first event and excluding events occurring in the hospital both lead to underestimation of overall event rates. There are inherent limitations to the timing of INR measures and clinical events. For example, it is possible that our associations with INR and hemorrhagic events are overestimated because of the presence of a consumptive coagulopathy. In terms of secular trends in anticoagulation management, the rate of pump thrombosis has been increasing over time, and anticoagulation and antiplatelet regimens have varied over time. 7, 8, 22 Although we did not quantify von Willebrand factor or platelet function, other LVAD studies have found that acquired von Willebrand deficiency contributes to GI bleeding. 23 Furthermore, screening for thrombosis has intensified, potentially resulting in more frequent detection of suspected pump thrombosis. Similarly, given our modest sample size, some putative risks for thrombosis, such as non-type O blood type, were not analyzed. 24 Finally, our event weighting may not be optimal because it was based on local mortality rates. There is almost no literature describing provider or patient weighting of LVADassociated adverse events. Given that pump thrombosis is associated with >50% 1-year mortality or major surgery with high morbidity, we chose to weigh it slightly greater than stroke. Literature in non-VAD supported patients has assigned GI bleeding weights between 0 and 0.6. 25 Modeling of optimal INR with a priori patient-or provider-derived weights for different events may a reasonable framework for prospective analyses of anticoagulation management.
In conclusion, INR and hemorrhagic events were highly correlated and INR and thrombotic events were inversely correlated. By considering both bleeding and thrombotic events, an optimal INR was determined to be 2.6, with low rates of adverse events falling between INR values of 2.0 to 3.2.
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